Table 2.

Benchmarking CIN2+ risks for negative follow-up tests following treatment for CIN2, CIN3 or AIS among women aged 25 and older, to CIN2+ risk thresholds implicitly used to determine clinical management options based on screening Pap tests.

Current recommended management strategy based on Pap-alone screening	Implicit risk threshold: 5-year CIN2+ risk (%)1 by baseline Pap-alonea result	Women treated for CIN2, CIN3, or AIS aged 25 and older
		Follow-up with Pap-alonea		Follow-up with HPV testing-aloneb		Follow-up with cotesting
		Pap result(s)	5-year CIN2+ risk after last test	HPV test result(s)	5-year CIN2+ risk after last test	HPV/Pap result(s)	5-year CIN2+ risk after last test
Immediate colposcopy	LSIL: 16%
6–12 month return	ASC-US: 6.9%	1 negative Pap	4.2%	1 negative HPV test	3.7%
Intermediate		2 negative Paps	2.7%	2 negative HPV tests	2.7%	1 negative cotest	2.4%
3-year return	Pap-: 0.68%					2 negative cotests	1.5%

^aFollow-up Pap result(s) alone (regardless of HPV test result)

^bFollow-up HPV test result(s) alone (regardless of Pap result)

¹Data presented in: Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, et al. Benchmarking CIN3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines J Low Genit Tract Dis In press.